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Creation of the Recombinant Tissue Plasminogen Activator (rt-PA) 
Image and Its Influence on Practice Habits* 
SOL SHERRY, MD, FACC, VICTOR J. MARDER, MDt 
Philadelphia, Pennsylvania and Rochester, New York 
American physicians have commonly practiced thrombolytic ther-
apy for acute myocardial infarction with the recombinant form of 
tissue plasminogen activator (rt-PA), although its cost is much 
higher than that of streptokinase. The greater popularity of rt-PA 
is based on the belief that it is a more effective and a safer drug for 
achieving myocardial salvage and mortality reduction. However, 
a series of studies testing this assumption have not substantiated 
its greater efficacy or safety with respect to not only streptokinase 
During 1990, approximately 75% of the patients treated in the 
United States with thrombolytic agents for an acute myocardial 
infarction received recombinant tissue-type plasminogen acti-
vator (rt-PA), 15% received streptokinase and a small propor-
tion received anisoylated plasminogen-streptokinase activator 
complex (APSAC) (1). Considering the expense ofrt-PA in its 
recommended dose (100 mg), sales of rt-PA could amount to 
$220 million as compared with $4 million for the relatively 
inexpensive streptokinase, a 55-fold difference. 
rt-PA versus streptokinase. This discrepancy between 
rt-P A and streptokinase usage and its cost to hospitals-and 
the even greater ultimate charge to patients and third party 
agencies, which we estimate at $0.5 billion for the former 
agent-is remarkable for two reasons. First, there is a lack of 
evidence that rt-P A therapy has greater clinical benefit or 
improved safety over streptokinase, as has been shown by 
trial results (2-9) and pointed out in editorials (1 0-12) and 
reviews (13-15). Second, European physicians, who use 
thrombolytic therapy more extensively than their counter-
parts in the United States and who are apparently more cost 
conscious and less impressed with the rt-PA data, prescribe 
streptokinase 80% of the time and rt-PA only 10%, the 
opposite of the experience in the United States. 
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but also urokinase and anisoylated plasminogen-streptokinase 
activator complex (APSAC). 
This editorial reviews the sequence of events that led to the 
creation of the rt-PA image, the mistaken premises on which it 
was based and the questions that need to be addressed if we are to 
strengthen the scientific method for evaluating similar types of 
drugs and its influence on practice habits including the costs to the 
health system. 
(]Am Coli Cardio/1991;18:1579-82) 
As of March 1991, compelling evidence has been pro-
vided against the superiority of rt-PA over other agents. The 
ISIS-3 (International Study on Infarct Survival-3) study (9) 
randomized patients with acute myocardial infarction to 
receive either streptokinase, APSAC or the double-stranded 
form of rt-PA, the type used in the original TIMI (Throm-
bolysis in Myocardial Infarction) Phase I trial (16). The 
mammoth ISIS-3 study involved approximately 46,000 pa-
tients, more than those in all previous thrombolytic trials 
combined, and it failed to demonstrate a therapeutic advan-
tage in survival for rt-PA over streptokinase or APSAC (9). 
Ironically, ISIS-3 documents that rt-PA causes a signifi-
cantly higher rate of hemorrhagic stroke than does streptoki-
nase, contrary to expectations that the "fibrin specificity" of 
rt-PA would serve to avert or minimize hemorrhagic com-
plications (17-19). On the basis of more limited studies, 
rt-PA is also unlikely to prove superior to urokinase or to 
single-chain urokinase (prourokinase) (20-23). 
The TIMI Phase I trial. Since the data do not justify the 
current preference for rt-PA by physicians (primarily cardi-
ologists) in the United States treating myocardial infarction, 
in terms of cost, efficacy or safety, it is necessary to examine 
the events that led to the current situation. The process can 
reasonably be traced to the very first comparative studies in 
humans, the TIMI Phase I trial (16) and the confirmatory 
European Cooperative Study Group trial utilizing a compa-
rable design (24). The primary end point ofreperfusion in the 
TIMI Phase I trial (not function or mortality) provided data 
that favored rt-PA by a striking 2:1 superiority over strep-
tokinase. This study began well enough, serendipitously 
undertaken in lieu of a planned trial by the National Heart, 
Lung, and Blood Institute that was to have compared 
intravenous versus intracoronary streptokinase. This course 
correction whereby the standard therapy with intravenous 
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streptokinase served as a trial horse for intravenous rt-PA 
was reasonable and timely. The trial presented a unique 
opportunity to significantly increase our understanding of 
thrombolytic therapy in general and of the comparative 
benefits of individual agents specifically, and to apply new 
insights into the treatment of a huge number of patients 
suffering from acute myocardial infarction (approximately 
500,000 each year in the United States alone). Unfortu-
nately, expectations for a new understanding of fundamental 
mechanisms and for their dramatic application to the public 
good have not been fully realized. Worse still, the current 
debate over the choice of agent to be used in the treatment of 
acute myocardial infarction appears to be taken by many 
physicians as an argument against the value of thrombolytic 
therapy in general, further threatening the full application of 
this important medical treatment. 
How did medical opinion arrive at the current state, in 
which rt-PA is strongly favored over streptokinase despite 
the results of clinical trials? In our view, the problem arises 
from three aspects of the highly influential TIMI-Phase I trial 
(16) relating to 1) weaknesses in the study design, 2) inter-
pretation of data, and 3) decisions about the succeeding 
(Phase II) studies. 
1. The primary end point of the trial. It is now clear that 
this end point, the incidence of coronary artery reperfusion 
at 90 miri after treatment induction, biased the results. Thus, 
follow-up coronary angiography was performed 30 min after 
the termination of infusion of streptokinase, at a time when 
the clot-dissolving activity of this agent was rapidly dimin-
ishing and reclotting and rethrombosis could be taking place. 
In contrast, the 90 min end point occurred at the mid-point of 
a 3-h rt-PA infusion when rapid lysis was continuing. Fur-
thermore, early rethrombosis (within I h) after the termina-
tion ofrt-PA therapy was known to be a significant problem 
with rt-PA (25), one that would negate the potential benefits 
of early reperfusion in a given patient, but it was not 
documented in this study because follow-up angiography 
was limited to the 90-min and predischarge views. Thus the 
arbitrary 90-min end point of TIMI Phase I would bypass the 
short (1 h) post-treatment coronary vessel status, which 
would have documented reocclusion more frequently after 
rt-PA than after streptokinase (26) whereas the predischarge 
follow-up only in patients with an open vessel would not 
have shown an increasing proportion of open vessels in the 
streptokinase group (27). Furthermore, the trial design was 
such that a disparity in 90-min reperfusion rates between 
patients treated with rt-PA and streptokinase was likely to be 
predictive of striking differences in function and clinical 
benefits on follow-up study. We now know that the results 
were quite different: namely, no such difference in ventric-
ular function (2-4) or survival (6,7,9) exists between strep-
tokinase and rt-PA-treated patients. 
2. The interpretation of the 90-min reperfusion results. 
This proved to be simplistic and misleading for reasons that 
are fully developed elsewhere (15) but can be summarized as 
follows. First, because increasing clot age (> 2 h) influenced 
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lysis rates with streptokinase but not with rt-PA (8,15,26,28), 
the mean delay of 4.8 h before treatment strongly favored the 
rt-PA group. Second, the rate of reperfusion at 90 min did 
not represent a maximum or stable end point because 
approximately 20% ofrt-PA-treated patients had early reoc-
clusion (29) whereas streptokinase-treated patients tended to 
show progressive coronary thrombolysis (15,30). Third, the 
primary end point was the demonstration of reperfusion at 
approximately 6.3 h after symptom onset, a time when 
significant myocardial salvage was unlikely (31 ,32), thereby 
eliminating the influence of late reperfusion on subsequent 
functional or clinical end points (15). 
The stress on the superiority of rt-P A therapy in terms of 
the rate of reperfusion at 90 min diverted attention from 
other outcomes and interpretations: 1) a higher rethrombosis 
rate with rt -PA (2,26); 2) the possibility that patency rates 
with streptokinase and rt-PA would be equivalent after a 
longer observation period-for example, at 3 to 24 h after 
treatment (15,30); 3) the irrelevance for salvage of myocar-
dium of a subsequent higher rate of reperfusion in coronary 
vessels subjected to > 3 h of thrombosis before thrombolytic 
therapy (15); and 4) the lack of functional or clinical superi-
ority of rt-PA in the TIMI-I trial itself (2,3), including the 
absence of any hemostatic advantage (5, 16) despite its 
fibrinogen-sparing effect (5,33). 
3. Choice of agents for the TIMI Phase II trial. The third 
aspect of TIMI Phase I that contributed to rt-PA's favored 
status has to do with the choice of agents for the Phase II 
trial. With the data of TIMI Phase I in hand, the National 
Heart, Lung, and Blood Institute and the TIMI Steering 
Committee had the following options. A, A trial comparing 
rt-PA with streptokinase in terms of clinical benefit and to 
determine whether the patency rate at 90 min is a reliable 
surrogate end point for myocardial function or mortality, or 
both. B, A trial comparing rt-PA not only with streptokinase, 
but also with other promising thrombolytic agents such as 
APSAC (34) or urokinase. C, A trial based on the "winner" 
concept in which only rt-PA would be utilized (35) assuming 
that the advantage in reperfusion rate obtained in TIMI 
Phase I would be translated into an equally impressive 
functional and clinical advantage. 
Since the 90-min snapshot of the coronary artery sug-
gested a twofold advantage of rt-PA over streptokinase, 
option 3 was chosen and streptokinase was dropped from 
further study by the TIMI program. This decision was taken 
despite concern over Phase II plans expressed by members 
of the Policy Advisory and Data Monitoring Board (subse-
quently replaced under a reorganization plan in May 1985). 
In dramatic fashion, the TIMI Phase I trial was stopped short 
in February 1985 because of "substantial, statistically sig-
nificant differences in recanalization rates'' (16). As reported 
in a preliminary report of the TIMI Phase I data published by 
The New England Journal of Medicine (16) in Aprill985 and 
the accompanying editorial (36), the investigators implied or 
concluded that streptokinase was so much less effective than 
rt-PA that it should not be studied further. Specifically, the 
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"Phase I findings" in the preliminary report (16) considered 
that " ... the incidence of recanalization 90 min after intra-
venous streptokinase is quite low; therefore, intravenous 
streptokinase appears to be of limited value in the treatment 
of acute myocardial infarction. Indeed, an early recan-
alization rate of only about one-third in patients with total 
occlusion raises concern about whether treatment with an 
agent with substantial side effects is justified on a routine 
basis." The editorial stated that " ... tissue-type plasmino-
gen activator holds more promise as an intravenous throm-
bolytic agent in acute myocardial infarction than does strep-
tokinase and clearly deserves further study ... " (36), but it 
did not recommend further trials to evaluate the clinical 
efficacy of streptokinase. 
Detailed analyses of the Phase I data were not published 
until 1987 and 1988. These showed, for example, a twofold 
higher reocclusion rate for rt-PA than for streptokinase (26), 
equal total and major bleeding events with both agents (5), 
no difference in ventricular functional changes (2) and no 
difference in subsequent clinical events or 1-year mortality 
(3). The decision to drop streptokinase from further study 
proved to be the greatest flaw in subsequent TIMI investi-
gations, for, instead of a continuing comparison of physio-
logic and clinical benefits of rt-PA and streptokinase (or 
other agents), Phase II studies focused only on overcoming 
the major weakness of rt-PA-its propensity for reocclu-
sion-and on maximizing the vascular response. The TIMI 
Phase II trial evaluated early elective angioplasty as a means 
of preventing reocclusion or reinfarction, or both (37), and 
other TIMI studies evaluated measures such as high dose 
rt-PA (38), while independent studies especially by the 
Thrombolysis and Angioplasty in Acute Myocardial Infarc-
tion (TAMI) group evaluated prolonged infusions of rt-PA 
(29), prostacyclin administration (39) or a combination of 
plasminogen activators (40,41). None of these studies has 
solved the rethrombosis problem with rt-PA therapy. Not 
only have these approaches not increased the stable patency 
rate significantly, but early angioplasty has proved to be a 
detriment rather than a benefit in comparison with clinically 
indicated angioplasty (37 ,42), and the attempt to administer 
high doses ofrt-PA exceeded the safety level with respect to 
intracranial hemorrhage (43). 
Other trials. By virtue of the decision to exclude strep-
tokinase from further study, rt-PA seemed to have received 
a stamp of approval from the National Heart, Lung, and 
Blood Institute. The latter part of 1985 and the beginning of 
1986 saw the end of the process for determining the drug of 
choice for thrombolytic therapy in the United States, and 
rt-PA was hailed as a wonder drug ("heart Drano") by the 
lay press (44,45). Left unsettled was the extent to which 
reperfusion or patency rates at 90 min truly or accurately 
reflected clinical benefit and whether other agents might 
have attributes equal to or even superior to those ofrt-PA for 
clinical efficacy or safety, despite the expenditure of multi-
millions of dollars of federal funds on behalf of rt-P A therapy 
in the various TIMI trials from 1985 to 1990. Fortunately, 
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excellent comparative trials organized in other countries, for 
example, the GISSI-2 trial (6), the ISIS-3 trial (9) and the 
New Zealand comparison (4), provided critical data. The 
information from all of these trials does not support the 
image originally promoted by the TIMI investigators (and 
the media) on the basis of mistaken predictions (15). 
Implications. There are important questions raised by 
this scenario describing the creation of the rt-PA image, for 
not only has it affected health care costs, but it has raised 
serious ethical and scientific concerns. For example, 1) to 
what extent has bias influenced decision making in trial 
design (46); 2) are there adequate safeguards in the mecha-
nism by which decision making occurs in the sponsorship of 
trials by the government; 3) how much do commercializa-
tion, politics, financial interests and aggrandizement inter-
fere with the scientific method; and 4) should safeguards be 
instituted to assure that public money is spent wisely. One 
hopes that the questions raised by the events leading to the 
precipitous but unfounded popularization ofrt-PA therapy in 
the United States will be addressed properly. 
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